EA201001224A1 - Химические соединения, композиции и способы их использования - Google Patents

Химические соединения, композиции и способы их использования

Info

Publication number
EA201001224A1
EA201001224A1 EA201001224A EA201001224A EA201001224A1 EA 201001224 A1 EA201001224 A1 EA 201001224A1 EA 201001224 A EA201001224 A EA 201001224A EA 201001224 A EA201001224 A EA 201001224A EA 201001224 A1 EA201001224 A1 EA 201001224A1
Authority
EA
Eurasian Patent Office
Prior art keywords
skeletal
methods
chemical compounds
muscle
compositions
Prior art date
Application number
EA201001224A
Other languages
English (en)
Russian (ru)
Inventor
Зхе Янг
Скотт Коллайби
Алекс Муци
Джианчао Ванг
Джефф Гардина
Льюк В. Ашкрафт
Брайан Стольц
Густав Берджинс
Брэдли П. Морган
Original Assignee
Цитокинетикс, Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цитокинетикс, Инкорпорейтед filed Critical Цитокинетикс, Инкорпорейтед
Publication of EA201001224A1 publication Critical patent/EA201001224A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
EA201001224A 2008-02-04 2009-02-02 Химические соединения, композиции и способы их использования EA201001224A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04
PCT/US2009/000686 WO2009099594A1 (en) 2008-02-04 2009-02-02 Certain chemical entities, compositions and methods

Publications (1)

Publication Number Publication Date
EA201001224A1 true EA201001224A1 (ru) 2011-08-30

Family

ID=40952391

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001224A EA201001224A1 (ru) 2008-02-04 2009-02-02 Химические соединения, композиции и способы их использования

Country Status (18)

Country Link
US (2) US7989469B2 (enExample)
EP (1) EP2244711A4 (enExample)
JP (1) JP2011510985A (enExample)
KR (1) KR20100119773A (enExample)
CN (1) CN101983061A (enExample)
AR (1) AR072242A1 (enExample)
AU (1) AU2009210787A1 (enExample)
BR (1) BRPI0907502A2 (enExample)
CA (1) CA2713864A1 (enExample)
CL (1) CL2009000246A1 (enExample)
CO (1) CO6290673A2 (enExample)
EA (1) EA201001224A1 (enExample)
EC (2) ECSP10010430A (enExample)
IL (1) IL207367A0 (enExample)
MX (1) MX2010008518A (enExample)
TW (1) TW200946524A (enExample)
WO (1) WO2009099594A1 (enExample)
ZA (1) ZA201005780B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
SG11201406359TA (en) * 2012-04-11 2014-11-27 Cytokinetics Inc Improving resistance to skeletal muscle fatigue
US20170042890A1 (en) 2014-04-29 2017-02-16 Cytokinetics, Inc. Methods of reducing decline in vital capacity
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
JP7592029B2 (ja) * 2019-05-28 2024-11-29 マンカインド ファーマ リミテッド ヤヌスキナーゼ1の阻害のための新規化合物
PE20240070A1 (es) * 2021-05-06 2024-01-11 Exscientia Ai Ltd MODULADORES DE PKC-theta
CN118702622A (zh) * 2024-08-30 2024-09-27 阜新达得利化工股份有限公司 一种3-溴-2-氰基吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
JP2007521296A (ja) 2003-07-01 2007-08-02 メルク エンド カムパニー インコーポレーテッド 高眼圧の治療のための眼科用組成物
EP1694323A4 (en) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
DK2583970T3 (en) 2006-08-02 2015-11-16 Cytokinetics Inc Certain chemical entities, compositions, and methods comprising imidazopyrimidines
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Mlk阻害剤および使用方法

Also Published As

Publication number Publication date
AR072242A1 (es) 2010-08-18
IL207367A0 (en) 2010-12-30
EP2244711A4 (en) 2011-08-24
CA2713864A1 (en) 2009-08-13
US20090253737A1 (en) 2009-10-08
EP2244711A1 (en) 2010-11-03
CO6290673A2 (es) 2011-06-20
US20110312975A1 (en) 2011-12-22
KR20100119773A (ko) 2010-11-10
TW200946524A (en) 2009-11-16
ECSP10010432A (es) 2011-01-31
AU2009210787A1 (en) 2009-08-13
WO2009099594A1 (en) 2009-08-13
MX2010008518A (es) 2010-11-10
CL2009000246A1 (es) 2009-06-26
JP2011510985A (ja) 2011-04-07
BRPI0907502A2 (pt) 2019-01-15
CN101983061A (zh) 2011-03-02
ZA201005780B (en) 2011-04-28
ECSP10010430A (es) 2011-02-28
US7989469B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
EA201001224A1 (ru) Химические соединения, композиции и способы их использования
WO2008016648A3 (en) Certain chemical entities, compositions and methods
MX2009001170A (es) Determinadas entidades quimicas, composiciones y metodos.
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
MEP59208A (en) Activin-actriia antagonists and uses for promoting bone growth
EA201300116A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
BR122020000059B8 (pt) composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
CY1121204T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige
EA202091708A1 (ru) Ингибиторы днк-пк
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
EA200700058A1 (ru) Соединения, композиции и способы их использования
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
HN2012002664A (es) Compuestos, composiciones de tioacetato y metodos de uso
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200970874A1 (ru) Антитела против склеростина